The U.S. Food and Drug Administration recently announced that Epclusa is now approved to treat adult patients with chronic hepatitis C virus (HCV), both with and without cirrhosis (advanced liver disease). Read the announcement to learn more about how this decision will widen the scope of treatment options for patients with HCV.
FDA Approves Epclusa for Treatment of Chronic Hepatitis C Infection
Jul 01, 2016 | Kim Rodgers
About Kim Rodgers
Pronouns: She/Her
Kim Rodgers was formerly the Communications Manager at NACCHO.
Related Posts
- Adverse Childhood Experiences (ACEs)
- Behavioral Health
- Community Health
- Injury and Violence Prevention
Seeking LHD Participants for an Intersectional Data...
With support from the Centers for Disease Control and Prevention, NACCHO is...
Mar 28, 2024 | Camille Adams
Seeking LHD Participants for an Intersectional Data...
- Mobilizing for Action through Planning and Partnerships (MAPP)
- Performance Improvement
- Workforce Development
Register to Attend a Mobilizing for Action through...
Registration is now open for NACCHO’s in-person Mobilizing for Action through...
Mar 23, 2024 | Andrea Grenadier